A phase II study comparing oral S-1 + 24-hour infusion of CPT-11 +bevacizumab with FOLFIRI+bevacizumab for metastatic colorectal cancer

ABSTRACT: Interventions: standard therapy group (FOLFIRI+bevacizumab) trial therapy arm (Oral S-1+24-hour infusion of CPT-11+bevacizumab) Primary outcome(s): 1 year progression-free survival Study Design: Parallel Randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2630001 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR